Status:
COMPLETED
Phase I Combination w/ Epirubicin
Lead Sponsor:
R-Pharm
Conditions:
Metastatic Breast Cancer
Eligibility:
FEMALE
18+ years
Phase:
PHASE1
Brief Summary
Tumor response information was obtained for all participants who received at least 2 cycles of study drug, underwent requisite baseline and on-treatment disease assessments and had at least one post-t...
Eligibility Criteria
Inclusion
- Women ≥18 years
- Histologically or cytologically confirmed diagnosis of metastatic breast cancer
- Measurable or nonmeasurable disease defined by Response Evaluation Criteria In Solid Tumors (RECIST)
Exclusion
- Number of prior chemotherapy lines of treatment in the metastatic setting ≥2
Key Trial Info
Start Date :
August 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2009
Estimated Enrollment :
42 Patients enrolled
Trial Details
Trial ID
NCT00322374
Start Date
August 1 2006
End Date
February 1 2009
Last Update
March 10 2016
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution
Toulouse, France, 31052
2
Local Institution
Milan, Italy, 20133